BESHAR LUKE M
Known title: DirectorCIK: 0001192128
BESHAR LUKE M's purchase track record
BESHAR LUKE M has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/30/2022 | TARA | $31K | +13.7% | -5.8% | +1.7% |
| 3/10/2022 | TARA | $87K | -19.9% | -21.9% | -5.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TARA | ▲ Buy | Open Market | 10,000 | $31K | 6/30/2022 | View on chart |
| TARA | ▲ Buy | Open Market | 10,000 | $43K | 3/14/2022 | View on chart |
| TARA | ▲ Buy | Open Market | 10,000 | $45K | 3/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment
Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.